Jan Lunemann

Professor

University of Münster

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jan Lunemann is a Professor at the University of Münster in Germany. His research areas include the immunological mechanisms in multiple sclerosis, B-cell behavior in autoimmune diseases, and the clinical implications of complement activation profiles. Recent articles by Professor Lunemann focus on topics such as disease-modifying therapies in multiple sclerosis, neuromyelitis optica, and the role of T cell responses in B cell regulation.

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Luisa María Villar

Universidad de Alcalá

SPAIN

View details

Ruth Geraldes

University of Oxford

UNITED KINGDOM

View details

Harald Neumann

Professor of Neural Regeneration

University of Bonn

GERMANY

View details

Stephan von Gunten

Associate Professor

University of Bern

SWITZERLAND

View details

Manuel Comabella

SPAIN

View details

Konrad Rejdak

Medical University of Lublin

POLAND

View details

Alessandro Dinoto

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY

View details

Falk Nimmerjahn

Full Professor

Friedrich-Alexander Universität Erlangen-Nürnberg

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jan Lunemann

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

ATG5 controls CD80 expression in B cells and shapes cognate CD4 + T cell responses

Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab

Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Moving beyond immunoglobulin therapy for CIDP with efgartigimod

Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.

Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset

Synthetic Cell-Based Immunotherapies for Neurologic Diseases

The CYP24A1 gene variant rs2762943 is associated with low serum 1,25‐dihydroxyvitamin D levels in multiple sclerosis patients

Autophagy pathways in autoimmune diseases

Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis

Impaired B Cell Expression of the Inhibitory Fcγ Receptor IIB in Myasthenia Gravis

Next-generation antibody-based therapies in neurology

Targeting sialylation to treat central nervous system diseases

ATG5 in microglia does not contribute vitally to autoimmune neuroinflammation in mice

Getting specific: targeting Fc receptors in myasthenia gravis

Targeting Inflammasomes to Treat Neurological Diseases

Collaborators (8)

Luisa María Villar

Ruth Geraldes

Harald Neumann

Stephan von Gunten

Manuel Comabella

Konrad Rejdak

Alessandro Dinoto

Falk Nimmerjahn

Make your next move.